BioMarin Announces Third Quarter 2018 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $99 at RBC Capital
October 26, 2018 7:09 AM EDTRBC Capital analyst Kennen MacKay raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $99.00 (from $98.00) while maintaining a Sector Perform rating following results.
The analyst notes strong Q3 with top/bottom line beats and tantalizing hints at pipeline updates at the upcoming Nov7 RnD Day.
... More
BioMarin Pharma (BMRN) Tops Q3 EPS by 15c, Offers Guidance
October 25, 2018 4:10 PM EDTBioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of ($0.07), $0.15 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $391.7 million versus the consensus estimate of $367.09 million.
GUIDANCE:
BioMarin Pharma sees FY2018 revenue of $1.47-1.53 billion, versus the consensus of... More
